We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing evorpacept (ALX148) as a foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 10:55:31 UTC

Jan 05, 2023

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

Jan 03, 2023

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia


ALX Oncology today provided a corporate update and highlighted key milestones anticipated in 2023: https://bit.ly/3XapVG3

ALX Oncology today announced the presentation of a company overview at the #JPM2023 Healthcare Conference. For additional details, visit: https://bit.ly/3i7SANg #JPM23

ALX Oncology will host a conference call on Tuesday, December 13, 2022 at 7:30 am EST to further discuss the initial AML data from ASPEN-05: https://bit.ly/3uPzaiM

Load More

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.